Indole

Indole

SCHEMBL3138428

C=CCN.c1ccc2[nH]ccc2c1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 7/20 0.65
TRPA1 O75762 1/20 0.65
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
ITGB2 P05107 1/20 0.65
ICAM1 P05362 1/20 0.65
ITGAL P20701 1/20 0.65
CA4 P22748 1/20 0.65
CA6 P23280 1/20 0.65
ADK P55263 1/20 0.65
NPC1 O15118 1/20 0.39
GFER P55789 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CYP2A6 P11509 3/20 0.35
CTNNB1 P35222 1/20 0.35
WNT3A P56704 1/20 0.35
NR4A2 P43354 2/20 0.34
CMA1 P23946 1/20 0.34
F7 P08709 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indole SCHEMBL6254730 0.85 AHR (0.65) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL26612366 0.85 AHR (0.65) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL28087845 0.84 AHR (0.77) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL28241238 0.82 AHR (0.74) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL2059954 0.82 AHR (0.74) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL5317626 0.81 AHR (0.61) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL10370373 0.81 AHR (0.90) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL10761451 0.81 AHR (0.90) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL1160186 0.81 AHR (1.00) AHRTRPA1CA1CA2ITGB2
Indole SCHEMBL698 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4185288-A1 THERAPEUTIC AGENTS AND USES THEREOF Ankh Life Sciences Limited (IE) 2023-05-31 EP disclosed
US-20220033417-A1 THERAPEUTIC AGENTS AND USES THEREOF ANKH LIFE SCIENCES LIMITED (IE) 2022-02-03 US disclosed
CN-113214247-A Azaindole derivative marrow cell proliferation inhibitor, preparation method and application thereof in pharmacy 复旦大学 2021-08-06 CN disclosed
CN-109071533-B Halogenated allylamine indole and azaindole derivative inhibitors of lysyl oxidase and uses thereof 法玛西斯有限公司 2021-05-25 CN disclosed
CN-109071533-B Halogenated allylamine indole and azaindole derivative inhibitors of lysyl oxidase and uses thereof 法玛西斯有限公司 2021-05-25 CN disclosed
CN-109071533-A Halogenated allylamine indoles and 7-azaindole derivatives inhibitor of lysyloxidase and application thereof 法玛西斯有限公司 2018-12-21 CN disclosed
CN-109071533-A Halogenated allylamine indoles and 7-azaindole derivatives inhibitor of lysyloxidase and application thereof 法玛西斯有限公司 2018-12-21 CN disclosed
US-20100210640-A1 BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF JIANGSU HENGRUI MEDICINE CO. LTD. (CN) 2010-08-19 US disclosed
EP-2189451-A1 BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210640-A1 BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF HTR4, HTR5A, TPH1 AHR 1136/4885TRPA1 128/4885CA1 4655/4885
US-20220033417-A1 THERAPEUTIC AGENTS AND USES THEREOF MCL1, BCL9, RNASE1 AHR 1187/4885TRPA1 3798/4885CA1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.